[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU94028712A - Полипептид, протеаза, днк, вектор, способ ингибирования активности, способ лечения - Google Patents

Полипептид, протеаза, днк, вектор, способ ингибирования активности, способ лечения

Info

Publication number
RU94028712A
RU94028712A RU94028712/13A RU94028712A RU94028712A RU 94028712 A RU94028712 A RU 94028712A RU 94028712/13 A RU94028712/13 A RU 94028712/13A RU 94028712 A RU94028712 A RU 94028712A RU 94028712 A RU94028712 A RU 94028712A
Authority
RU
Russia
Prior art keywords
asp
amino acid
protease
ala
acid sequence
Prior art date
Application number
RU94028712/13A
Other languages
English (en)
Other versions
RU2206611C2 (ru
Inventor
А.Блэк Рой
Us]
Р.Смит Паул
Р.Кронхейм Ширлей
Original Assignee
Стерлинг Уинтроп
Стерлинг Уинтроп, Инк.
Инк. (US)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Стерлинг Уинтроп, Стерлинг Уинтроп, Инк., Инк. (US) filed Critical Стерлинг Уинтроп
Publication of RU94028712A publication Critical patent/RU94028712A/ru
Application granted granted Critical
Publication of RU2206611C2 publication Critical patent/RU2206611C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8142—Aspartate protease (E.C. 3.4.23) inhibitors, e.g. HIV protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)

Abstract

Предложен изолированный полипептид и его производные, обладающие протеазной биологической активностью для человеческого предшественника ИЛ- Iβ и для субстрата, состоящего из R- Asp - R- R, где Rи Rнезависимо являются любым D или L изомером аминокислоты, Rявляется Ala или Gly, сайт специфического протеазного расщепления находится между Asp и R. Также предложены ингибирующие соединения, композиции и способы ингибирования интерлейкин-Iβ протеазной активности. Ингибирующие соединения представляют собой аминокислотную последовательность из 1 до примерно 5 аминокислот, имеющую N-концевую блокирующую группу и С-концевой Asp остаток, соединенный с электроотрицательной отщепляемой группой, причем аминокислотная последовательность соответствует последовательности Ala-Tyr-Val-His-Asp.

Claims (1)

  1. Предложен изолированный полипептид и его производные, обладающие протеазной биологической активностью для человеческого предшественника ИЛ- Iβ и для субстрата, состоящего из R1 - Asp - R2 - R3, где R1 и R3 независимо являются любым D или L изомером аминокислоты, R2 является Ala или Gly, сайт специфического протеазного расщепления находится между Asp и R2. Также предложены ингибирующие соединения, композиции и способы ингибирования интерлейкин-Iβ протеазной активности. Ингибирующие соединения представляют собой аминокислотную последовательность из 1 до примерно 5 аминокислот, имеющую N-концевую блокирующую группу и С-концевой Asp остаток, соединенный с электроотрицательной отщепляемой группой, причем аминокислотная последовательность соответствует последовательности Ala-Tyr-Val-His-Asp.
RU94028712/13A 1991-08-30 1991-09-12 ФРАГМЕНТ ДНК, ПЛАЗМИДНЫЙ ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ IL-1β ПРОТЕАЗНОЙ АКТИВНОСТЬЮ RU2206611C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75064491A 1991-08-30 1991-08-30
US750,644 1991-08-30

Publications (2)

Publication Number Publication Date
RU94028712A true RU94028712A (ru) 1997-03-10
RU2206611C2 RU2206611C2 (ru) 2003-06-20

Family

ID=25018683

Family Applications (2)

Application Number Title Priority Date Filing Date
RU94028712/13A RU2206611C2 (ru) 1991-08-30 1991-09-12 ФРАГМЕНТ ДНК, ПЛАЗМИДНЫЙ ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ IL-1β ПРОТЕАЗНОЙ АКТИВНОСТЬЮ
RU2002128757/13A RU2002128757A (ru) 1991-08-30 2002-10-25 Полипептид, протеаза, днк, вектор, способ получения протеазы, соединения, композиции, способ ингибирования активности, способ лечения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2002128757/13A RU2002128757A (ru) 1991-08-30 2002-10-25 Полипептид, протеаза, днк, вектор, способ получения протеазы, соединения, композиции, способ ингибирования активности, способ лечения

Country Status (22)

Country Link
US (2) US5756465A (ru)
EP (2) EP1378573A1 (ru)
JP (3) JP2759895B2 (ru)
KR (1) KR100226296B1 (ru)
AT (1) ATE257517T1 (ru)
AU (1) AU657701B2 (ru)
CA (1) CA2111100C (ru)
DE (1) DE69133354T2 (ru)
DK (1) DK0600880T3 (ru)
ES (1) ES2213138T3 (ru)
FI (1) FI935020A (ru)
HK (1) HK1014013A1 (ru)
HU (1) HU220098B (ru)
IE (1) IE913268A1 (ru)
IL (2) IL99598A (ru)
MX (1) MX9101346A (ru)
MY (1) MY131144A (ru)
NO (1) NO317129B1 (ru)
NZ (3) NZ335312A (ru)
PT (1) PT99118B (ru)
RU (2) RU2206611C2 (ru)
WO (1) WO1993005071A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2486244C2 (ru) * 2007-10-30 2013-06-27 ДАНИСКО ЮЭс ИНК. ПРОТЕАЗА Streptomyces

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US6995141B1 (en) 1990-04-04 2006-02-07 Vertex Pharmaceuticals Incorporated Interleukin 1β protease and interleukin 1β protease inhibitors
JP2759895B2 (ja) * 1991-08-30 1998-05-28 サノフィ インターロイキン１βプロテアーゼをコードするＤＮＡ配列単離体
IL105741A0 (en) * 1992-05-22 1993-09-22 Genta Inc Pharmaceutical compositions for treating cellular hyperproliferation using interleukin-1 inhibitory compounds
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
JPH0789951A (ja) * 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
ATE170868T1 (de) * 1993-06-04 1998-09-15 Vertex Pharma Peptid-phosphinyloxymethyl-ketonen als inhibitoren von interleukin-1 beta- konvertierenden enzymen
US5843905A (en) * 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
CA2165777A1 (en) * 1993-06-24 1995-01-05 Junying Yuan Programmed cell death genes and proteins
US6087160A (en) * 1993-06-24 2000-07-11 The General Hospital Corporation Programmed cell death genes and proteins
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5955072A (en) 1994-07-13 1999-09-21 Sankyo Company, Limited Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
CA2202549C (en) * 1994-10-14 2003-08-05 Tara Seshadri Transgenic nonhuman animal having functionally disrupted interleukin-1.beta. converting enzyme gene
CA2215211A1 (en) * 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5869315A (en) 1995-12-18 1999-02-09 Basf Aktiengesellschaft Modified interleukin-1β converting enzyme with increased stability
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US6288037B1 (en) 1996-01-29 2001-09-11 Basf Aktiengesellschaft Substrates and inhibitors for cysteine protease ICH-1
US6416753B1 (en) 1996-03-15 2002-07-09 The General Hospital Corporation Method for modulating apoptosis
US6531467B2 (en) 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6610683B2 (en) 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
KR100580333B1 (ko) * 1997-10-10 2006-05-16 시토비아 인크. 디펩티드 고사 억제제 및 그의 용도
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
ES2244178T3 (es) 1998-03-09 2005-12-01 Vertex Pharmaceuticals Incorporated Derivados de 1,2-diazepan como inhibidores de la enzima convertidora de interleuquina-1 beta.
KR20010041905A (ko) * 1998-03-16 2001-05-25 시토비아 인크. 디펩티드 카스파제 억제제 및 이의 용도
JP4594520B2 (ja) 1998-03-19 2010-12-08 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼのインヒビター
ATE336480T1 (de) 1999-03-16 2006-09-15 Cytovia Inc Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
DE19915465A1 (de) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten
DE60035037T2 (de) 1999-04-09 2008-01-31 Cytovia, Inc., San Diego Caspase inhibitoren und ihre verwendung
JP2003502316A (ja) * 1999-06-14 2003-01-21 ウィスコンシン アルムニ リサーチ ファウンデイション 環状イミノカルボン酸のオリゴマー及びポリマー
WO2001016093A1 (en) 1999-08-27 2001-03-08 Cytovia, Inc. SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
SI1268425T1 (sl) 2000-03-29 2008-04-30 Vertex Pharma Zaviralci karbamat kaspaze in uporaba le-teh
WO2001072707A2 (en) 2000-03-29 2001-10-04 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
EP1282435A2 (en) 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US7153822B2 (en) * 2002-01-29 2006-12-26 Wyeth Compositions and methods for modulating connexin hemichannels
CA2484959A1 (en) 2002-04-30 2003-11-13 Yungjin Pharmaceutical Co., Ltd. Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
KR20060088543A (ko) * 2003-09-25 2006-08-04 디엠아이 바이오사이언스 인코포레이티드 앤-아실-엘-아스파틱산을 이용하는 방법 및 제품
WO2005117846A2 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
WO2005115362A1 (en) * 2004-05-15 2005-12-08 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2012061786A1 (en) 2010-11-05 2012-05-10 Brandeis University Ice cleaved alpha-synuclein a biomarker
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984000365A1 (en) * 1982-07-19 1984-02-02 Nat Res Dev Synthetic peptides and their preparation
US4636492A (en) * 1984-08-29 1987-01-13 E. I. Du Pont De Nemours And Company Inhibition of viral protease activity by peptide halomethyl ketones
US5104853A (en) * 1984-12-11 1992-04-14 California Biotechnology Inc. Alveolar surfactant proteins having cys to ser mutations
JPS63145300A (ja) * 1984-12-17 1988-06-17 イ−・アイ・デユポン・デ・ニモアス・アンド・カンパニ− ウイルスにより特定されているプロテア−ゼの特異的阻害剤を製造する方法
US4644055A (en) * 1984-12-17 1987-02-17 E. I. Du Pont De Nemours And Company Method for preparing specific inhibitors of virus-specified proteases
US5225354A (en) * 1986-08-22 1993-07-06 Molecular Diagnostics, Inc. Monoclonal antibodies specific for human glycoalbumin
WO1991000912A1 (en) * 1989-07-07 1991-01-24 Massachusetts Institute Of Technology Production and use of hybrid protease inhibitors
AU7775991A (en) * 1990-04-04 1991-10-30 Immunex Corporation Interleukin 1beta protease
US5298421A (en) * 1990-04-26 1994-03-29 Calgene, Inc. Plant medium-chain-preferring acyl-ACP thioesterases and related methods
EP0533350B1 (en) * 1991-08-16 1999-05-26 Merck & Co. Inc. DNA encoding precursor interleukin 1B converting enzyme
JP2759895B2 (ja) * 1991-08-30 1998-05-28 サノフィ インターロイキン１βプロテアーゼをコードするＤＮＡ配列単離体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2486244C2 (ru) * 2007-10-30 2013-06-27 ДАНИСКО ЮЭс ИНК. ПРОТЕАЗА Streptomyces

Also Published As

Publication number Publication date
NZ239895A (en) 1996-01-26
PT99118B (pt) 1999-02-26
FI935020A (fi) 1993-12-03
EP0600880A4 (en) 1994-12-21
HU220098B (hu) 2001-10-28
MX9101346A (es) 1993-02-01
IL166791A0 (en) 2006-01-15
FI935020A0 (fi) 1993-11-12
CA2111100A1 (en) 1993-03-18
PT99118A (pt) 1993-02-26
JP2001192397A (ja) 2001-07-17
AU8537391A (en) 1993-04-05
EP0600880B1 (en) 2004-01-07
HU9303244D0 (en) 1994-03-28
ES2213138T3 (es) 2004-08-16
DE69133354D1 (de) 2004-02-12
NZ248377A (en) 2000-01-28
IE913268A1 (en) 1993-03-10
US5756465A (en) 1998-05-26
JPH08505280A (ja) 1996-06-11
JP2759895B2 (ja) 1998-05-28
JP3445572B2 (ja) 2003-09-08
CA2111100C (en) 2004-11-02
DK0600880T3 (da) 2004-04-13
MY131144A (en) 2007-07-31
EP1378573A1 (en) 2004-01-07
NO317129B1 (no) 2004-08-23
EP0600880A1 (en) 1994-06-15
NO934335L (no) 1993-11-30
RU2206611C2 (ru) 2003-06-20
WO1993005071A1 (en) 1993-03-18
KR100226296B1 (ko) 1999-10-15
JPH1028588A (ja) 1998-02-03
NZ335312A (en) 2005-08-26
US6136787A (en) 2000-10-24
IL99598A0 (en) 1992-08-18
ATE257517T1 (de) 2004-01-15
NO934335D0 (no) 1993-11-30
IL99598A (en) 2005-06-19
RU2002128757A (ru) 2004-07-27
HK1014013A1 (en) 1999-09-17
AU657701B2 (en) 1995-03-23
HUT66057A (en) 1994-09-28
DE69133354T2 (de) 2004-11-11

Similar Documents

Publication Publication Date Title
RU94028712A (ru) Полипептид, протеаза, днк, вектор, способ ингибирования активности, способ лечения
Püschel et al. Isolation and characterization of dipeptidyl peptidase IV from human placenta
Harboe et al. The Activation of Bovine Pepsinogen: SEQUENCE OF THE PEPTIDES RELEASED, IDENTIFICATION OF A PEPSIN INHIBITOR
Walker et al. The primary structure of the nucleosome-associated chromosomal protein HMG 14
HU207102B (en) Process for producing peptidase inhibitors
EP0035383B1 (en) Angiotensin converting enzyme inhibitors
Conlon et al. A protease inhibitor of the Kunitz family from skin secretions of the tomato frog, Dyscophus guineti (Microhylidae)
WO2003089457B1 (en) Peptide inhibitors of protein kinase c ϝ for pain management
English et al. The enzyme stability of dehydropeptides
EP0418233A1 (en) Cysteine proteinase inhibitor
Neurath et al. III. Carboxypeptidase bovine carboxypeptidase A—activation, chemical structure and molecular heterogeneity
MOLLAY et al. Isolation of a dipeptidyl aminopeptidase, a putative processing enzyme, from skin secretion of Xenopus laevis
US5229367A (en) Antiinflammatory peptide derived from human lipocortin V
DE68923625T2 (de) Enzymatischer Prozess zur Herstellung immunomodulatorischer Pentapeptide und Intermediate zu deren Herstellung.
Burzio et al. The adhesive protein of Choromytilus chorus (Molina, 1782) and Aulacomya ater (Molina, 1782): a proline-rich and a glycine-rich polyphenolic protein
Setlow et al. The complete covalent structure of protein B. The third major protein degraded during germination of Bacillus megaterium spores.
Richards et al. Characterization of a lysyl aminopeptidase activity associated with phosphoglucose isomerase of Vibrio vulnificus
US5374713A (en) Peptide inhibitors of phospholipase A2 purified from inflammatory sites
SiEKMANN et al. Pyroglutamyl-aprotinin, a new aprotinin homologue from bovine lungs-isolation, properties, sequence analysis and characterization using 1H nuclear magnetic resonance in solution
JP4485048B2 (ja) プロリルエンドペプチダーゼ阻害ペプチド
JP3353052B2 (ja) 酵素を用いるペプチド合成方法
Nakagomi et al. Isolation of novel peptides, cabin-1,-2,-3, and-4, that inhibit cathepsin B from a thermolysin digest of human plasma
Edwards et al. Pigeon muscle aldolase: Kinetic properties and primary structure close to the substrate binding lysine residue
JPH04237498A (ja) ペプチドの製造法
JPH07133299A (ja) ゼラチナーゼａ活性阻害剤

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20050913